Merck & Company Inc (MRK)vsAnbio Biotechnology Class A Ordinary Shares (NNNN)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
NNNN
Anbio Biotechnology Class A Ordinary Shares
$28.50
+3.90%
HEALTHCARE · Cap: $1.20B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 751750% more annual revenue ($65.01B vs $8.65M). NNNN leads profitability with a 74.1% profit margin vs 28.1%. MRK trades at a lower P/E of 15.2x. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
NNNN
Buy52
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Intrinsic value data unavailable for NNNN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Keeps 74 of every $100 in revenue as profit
Strong operational efficiency at 59.1%
Revenue surging 73.9% year-over-year
Every $100 of equity generates 27 in profit
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
2.8% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Trading at 41.3x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : NNNN
The strongest argument for NNNN centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 74.1% and operating margin at 59.1%. Revenue growth of 73.9% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : NNNN
The primary concerns for NNNN are EPS Growth, Market Cap, P/E Ratio. A P/E of 182.9x leaves little room for execution misses.
Key Dynamics to Monitor
MRK profiles as a value stock while NNNN is a growth play — different risk/reward profiles.
NNNN is growing revenue faster at 73.9% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
MRK scores higher overall (59/100 vs 52/100), backed by strong 28.1% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Anbio Biotechnology Class A Ordinary Shares
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?